{"ModuleTitle": "Company Description", "CompanyName": "Fate Therapeutics, Inc.", "Symbol": "FATE", "Address": "3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO, California, 92121, United States of America", "Phone": "858.875.1803", "Industry": "Biotechnology: Biological Products (No Diagnostic Substances)", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a clinical-stage biopharmaceutical company dedicated to the development\r\nof programmed cellular immunotherapies for cancer and immune disorders. We are\r\ndeveloping first-in-class cell therapy product candidates based on a simple\r\nnotion: we believe that better cell therapies start with better cells.\r\n\r\nTo create better cell therapies, we use a therapeutic approach that we generally\r\nrefer to as cell programming. For certain of our product candidates, we use\r\npharmacologic modulators, such as small molecules, to enhance the biological\r\nproperties and therapeutic function of allogeneic, or healthy donor-sourced,\r\ncells ex vivo before our product candidates are administered to a patient. In\r\nother cases, we use human induced pluripotent stem cells (iPSCs) to generate a\r\nclonal master iPSC line having preferred biological properties and direct the\r\nfate of the clonal master iPSC line to create our cell therapy product\r\ncandidate.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f02%2f0001564590-20-008141.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Daniel D. Shoemaker", "title": "Chief Scientific Officer"}, {"name": "J. Scott Wolchko", "title": "President, Chief Executive Officer & Director"}, {"name": "Wen Bo Wang", "title": "Senior Vice President-Technical Operations"}, {"name": "Yu Waye Chu", "title": "Senior Vice President-Clinical Development"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}